Factbites
 Where results make sense
About us   |   Why use us?   |   Reviews   |   PR   |   Contact us  

Topic: Celera Genomics


Related Topics

  
  Celera Genomics: Our History
Celera was founded in 1998 with the mission to sequence the human genome and provide clients with early access to the resulting data.
Celera Genomics received a milestone payment from Merck recognizing Merck’s advancement of a Cathepsin K inhibitor into a Phase I clinical trial as a potential treatment for osteoporosis.
Celera Genomics and Abbott announced that two Celera antigen targets were selected for further investigation by Abbott for therapeutic development.
www.celera.com /celera/history   (1451 words)

  
 washingtonpost.com: Celera Genomics Says Loss Narrowed as Revenue Fell
Celera, a unit of Applera Corp. of Norwalk, Conn., said last year that it would withdraw from the gene-hunting business, which propelled its stock to more than $250 a share in 2000, and begin translating its patented genetic insights into commercial drugs.
Celera predicted that it will have revenue of $85 million to $95 million in the fiscal year ending in June, the majority of it from royalty payments tied to its former online genetic data unit, which is profitable.
Celera Diagnostics, a joint venture between Celera Genomics and Applied Biosystems, said its second-quarter revenue surged to $7.8 million, from $1.9 million a year earlier.
www.washingtonpost.com /ac2/wp-dyn/A35317-2003Jan23?language=printer   (513 words)

  
 Celera FAQs
The Celera Genomics Group is primarily a molecular diagnostics business that is using proprietary genomics and proteomics discovery platforms to identify and validate novel diagnostic markers, and is developing diagnostic products based on these markers as well as other known markers.
Celera Genomics maintains a strategic alliance with Abbott Laboratories for the development and commercialization of molecular, or nucleic acid-based, diagnostic products, and it is also developing new diagnostic products outside of this alliance.
Celera Genomics was a start-up business in the new area of genomics, where substantial time and investment were anticipated to precede ultimate business success.
www.corporate-ir.net /ireye/ir_site.zhtml?ticker=CRA&script=1801   (2015 words)

  
 RedOrbit - Health - Celera Genomics Receives NIH Grant to Develop and Commercialize Avian Flu Diagnostic Test   (Site not responding. Last check: 2007-09-17)
Celera Genomics is primarily a molecular diagnostics business that is using proprietary genomics and proteomics discovery platforms to identify and validate novel diagnostic markers, and is developing diagnostic products based on these markers as well as other known markers.
Celera Genomics maintains a strategic alliance with Abbott for the development and commercialization of molecular, or nucleic acid-based, diagnostic products, and it is also developing new diagnostic products outside of this alliance.
Celera is a registered trademark and Applera, Applied Biosystems and Celera Genomics are trademarks of Applera Corporation or its subsidiaries in the U.S. and/or certain other countries.
www.redorbit.com /news/health/625466/celera_genomics_receives_nih_grant_to_develop_and_commercialize_avian/?source=r_health   (857 words)

  
 Celera Genomics - Wikipedia, the free encyclopedia
Celera Genomics was established in May 1998 by the Perkin-Elmer Corporation (and was later purchased by Applera Corporation), with Dr. J.
Celera was formed for the purpose of generating and commercializing genomic information to accelerate the understanding of biological processes.
Prepared Statement of Craig Venter of Celera Venter discusses Celera's progress in deciphering the human genome sequence and its relationship to healthcare and to the federally funded Human Genome Project.
en.wikipedia.org /wiki/Celera_Genomics   (423 words)

  
 Celera Genomics   (Site not responding. Last check: 2007-09-17)
Celera Genomics was established in 1998 to help unlock the human genome and completely sequence the three billion units in human DNA.
Celera also continues to serve its large commercial and enterprise clients by offering complete access to the best set of genomics data and tools available, with all public and proprietary data integrated in flexible and compatible platforms.
Celera Genomics is the world's preeminent commercial source of information based on the human genome and related biological and medical data.
www.macrovision.com /products/erights/case_studies/celera.shtml   (1015 words)

  
 Celera Genomics
Under the auspices of Applera Corporation, Celera Genomics is engaged primarily in the discovery and development of targeted therapeutics for cancer as well as for autoimmune and inflammatory diseases.
One of the founders of Celera was J. Craig Venter, the maverick geneticist who sparked the famed race with the publicly-funded Human Genome Project (HGP), an international consortium of government and academic scientists in the United States and Europe, to produce the first map of the human genome.
Celera would utilize his rapid fire method known as the "random shotgun" approach, which served to sequence bits of genes that were pieced together in the end to create a map.
www.referenceforbusiness.com /history/Ca-Ch/Celera-Genomics.html   (3325 words)

  
 TDR Celebrates 115 Years - Celera Genomics: Mapping the human genetic blueprint   (Site not responding. Last check: 2007-09-17)
The Human Genome Project, the “mapping” of the entire human genetic blueprint, began in earnest in the United States in 1990 with increased funding from the National Institutes of Health and the Department of Energy.
In 1998, Celera Genomics, a private biotechnology company in Rockville, began a separate project intended to speed up the sequencing process and commercialize the results in three years or less.
Celera’s founder and genomics pioneer J. Craig Venter was among those who left the company when it refocused on drug development.
www.mddailyrecord.com /honors/celera.html   (522 words)

  
 Celera Genomics News
Celera Genomics shares rose for a second day after forecasting a move to profitability by the end of fiscal 2008 and a strong operating performance by 2011.
Celera Genomics has announced that it has developed a genetic test to help predict which hepatitis C patients will eventually suffer liver scarring and so are most in need of treatment.
Maryland-based Celera Genomics on Wednesday was expected to announce a genetic test that it says could predict if a patient with hepatitis C is likely to develop cirrhosis of the liver, the New York Times...
www.topix.net /com/celera-genomics   (731 words)

  
 Fool.com: Dueling Fools, Et Celera, Etcetera
Celera isn't the only genomics player in town, but it sure does appear to be the Michael Jordan of its niche.
Celera just focused its sequencing efforts on the human genome some nine months ago, yet it was able to completely finish sequencing one human genome last month.
Celera has the capital, the brainpower, and the entrepreneurial spirit to pursue this enormous opportunity and create value both for its shareholders and for humankind.
www.fool.com /duelingfools/2000/duelingfools00060701.htm   (866 words)

  
 News: Celera Genomics Reports Fourth Quarter and Fiscal 2006 Results. Genetic Engineering News - Biotechnology from ...
Celera Genomics Group (NYSE:CRA), an Applera Corporation business, today reported a net loss of $5.3 million, or $0.07 per share, for the fourth quarter of fiscal 2006 ended June 30, 2006, compared to a net loss of $16.4 million, or $0.22 per share, for the fourth quarter of fiscal 2005.
Celera will be entitled to royalty payments up to the low double digit percentages based on annual sales of any drugs commercialized from the program.
Celera Genomics anticipates that its fiscal 2007 financial performance will be affected by continued growth in demand for current and new diagnostic products and potential revenue from technology licenses and collaborations.
www.genengnews.com /news/bnitem.aspx?name=3757931   (2245 words)

  
 News: Celera Genomics Reports Third Quarter Fiscal 2006 Results. Genetic Engineering News - Biotechnology from Bench to ...
Celera Genomics Group (NYSE:CRA), an Applera Corporation business, today reported a net loss of $23.3 million, or $0.31 per share, for the third quarter of fiscal 2006 ended March 31, 2006, compared to a net loss of $21.0 million, or $0.29 per share, for the third quarter of fiscal 2005.
Prior to that date, Celera Genomics accounted for its interest in the Celera Diagnostics joint venture under the equity method of accounting and included 100 percent of the losses of Celera Diagnostics in its statement of operations as 'Loss from joint venture'.
Celera Genomics anticipates that its fiscal 2006 financial performance will be affected by, among other things, continued growth in demand for current and new diagnostic products and potential revenue from technology licenses and collaborations.
www.genengnews.com /news/bnitem.aspx?name=831995   (2244 words)

  
 Genomics Collaborative Inc.   (Site not responding. Last check: 2007-09-17)
The Celera Genomics Group, located in Rockville, MD, and South San Francisco, CA, is engaged principally in integrating advanced technologies to discover and develop new therapeutics.
Celera intends to leverage its proteomics, bioinformatics, and genomics capabilities to identify and validate drug targets and diagnostic marker candidates, and to discover and develop novel therapeutic candidates.
Genomics Collaborative, Inc. ("GCI") is a functional genomics company with a clinical approach to discovery, focused on developing high value, proprietary intellectual property on its own account and in collaboration with bio-pharmaceutical companies and academic medical centers.
www.genomicsinc.com /press_release_18.html   (796 words)

  
 Celera Genomics Files Investigational New Drug Application For   (Site not responding. Last check: 2007-09-17)
Celera Genomics recently reported data at the American Association for Cancer Research (AACR) meeting in April 2005, showing the efficacy of CRA-024781 as an HDAC inhibitor in xenograft cancer models.
Celera Genomics published the first three-dimensional structure of an HDAC enzyme in July 2004, and this information has been used to aid the design of a series of novel HDAC inhibitors.
Celera Genomics has another compound, a Cathepsin K inhibitor, in a Phase I clinical trial as a potential treatment for osteoporosis.
www.bioresearchonline.com /content/news/article.asp?docid={A26A9585-334F-4FD9-BC7D-4ACF9EDB5969}&VNETCOOKIE=NO   (578 words)

  
 Celera Genomics Group-an Applera Corp. Business
Celera Genomics is engaged in the discovery and development of targeted therapies for cancer, autoimmune and inflammatory diseases.
Through Celera Diagnostics, its 50/50 joint venture with Applied Biosystems, Celera Genomics is participating in the development of new molecular diagnostic products for a wide array of common, complex diseases, such as chronic heart disease, rheumatoid arthritis, and breast cancer.
Celera Genomics has focused its efforts on advancing its small molecule programs, and on the discovery of associations between cell surface proteins and cancer.
www.biospace.com /company_profile.aspx?CompanyID=3812   (444 words)

  
 Wired News: Celera Wins Genome Race
Although Venter denied that Celera was actually racing the public project, the two groups have been competitive in the past.
Celera said it filed for 6,500 patents on gene sequences last year, but now says it has only submitted preliminary paperwork on the genetic information and will only ask for patents on genes that may be significant for drug development.
The Human Genome Project has said it will soon have a first draft of 90 percent of the human genome with four to five times coverage (redundant mapping for accuracy), and expects to have a final draft in 2002 or 2003.
www.wired.com /news/technology/0,1282,35479,00.html   (843 words)

  
 Celera Genomics' losses widen in 4Q - Jul. 27, 2000
NEW YORK (CNNfn) - Celera Genomics Group, the upstart company that announced last month it had mapped virtually all of the genes in the human body, reported widening losses for its fiscal fourth quarter Thursday as it spent heavily on research and development.
Celera, based in Rockville, Md., lost $20.4 million, or 35 cents per diluted share, during the quarter ended June 30, compared with a loss of $19.9 million, or 39 cents per diluted share, in the year-earlier period.
Celera is not expected to turn a profit until at least fiscal 2002-2003.
money.cnn.com /2000/07/27/companies/celera/index.htm   (774 words)

  
 Abbott selects two more cancer targets from Celera deal   (Site not responding. Last check: 2007-09-17)
Celera Genomics has announced that Abbott has selected two additional cancer targets for further development, which brings the total of targets to four under investigation as a result of the collaboration between the companies to discover and commercialise therapies for cancer treatment.
Under the terms of the collaboration agreement, a number of protein antigens identified and validated by Celera Genomics are being screened by Abbott.
Celera now have five antigens in the research pipeline with their partners, and are working to move additional targets forward for therapeutic development through current and future collaborations.
www.drugresearcher.com /news/ng.asp?n=66045-celera-genomics-abbott-cancer-targets   (395 words)

  
 Celera Genomics Corporation Project
Celera Genomics Corporation made history in 2000 by becoming the first scientific research firm to successfully map the human genome.
Celera's explosive research with the human genome required an expansion of their data center and the installation of a new DNA Sequencing Facility.
The employees of the Celera Genomics Corporation occupied the facility throughout the entire duration of Poole and Kent's contract.
www.poole-kent.com /services/projects/proj_celera.html   (311 words)

  
 Abbott Laboratories and Celera Genomics Announce Cancer Therapeutics Collaboration   (Site not responding. Last check: 2007-09-17)
Celera Genomics will contribute a subset of the cell–surface antigens that it has identified and validated through its ongoing proteomic studies in a number of solid tumors.
Celera intends to leverage its proteomic, bioinformatic, and genomic capabilities to identify and validate drug targets, and to discover and develop new therapeutics.
Celera Diagnostics, a 50/50 joint venture between Applied Biosystems and Celera Genomics, is focused on discovery, development, and commercialization of novel diagnostic products.
www.abbott.com /global/url/pressRelease/en_US/60.5:5/Press_Release_0053.htm   (989 words)

  
 Fool.com: Celera Bites the Dust [Rule Breaker] April 23, 2002
In December 1999, Celera Genomics was the top dog in the important emerging industry of bioinformatics, but it failed to fulfill its promise.
Celera will have revenue from Applied Biosystems and it does own 50% of Celera Diagnostics, but we are persuaded by Human Genome Sciences' CEO William Haseltine that diagnostics has not been nor will be a very lucrative business.
Celera may have a future as a profitable operation of Applera Corp., but is no longer a Rule Breaker and offers us no foreseeable possibility of outstanding returns to compensate for its significant risk.
www.fool.com /portfolios/rulebreaker/2002/rulebreaker020423.htm   (1785 words)

  
 Celera Genomics Announcement from AP
The milestone puts the company, Celera Genomics of Rockville, MD, far ahead of an international government effort to map the human genome using a different method.
"I don't believe a genome is done until there is an attempt to identify the genes and the linear sequence along all of the chromosomes," he said.
But, in contrast to Celera, the Federal Project is releasing to the public the genetic sequences as they are identified.
www.grg.org /celera040600.htm   (701 words)

  
 Storage Networking World Online - Celera Genomics turns SAN islands into a global entity
When Celera Genomics Group was in the throes of the human genome sequencing project, it was not uncommon for a user to wander in late on a Friday afternoon and ask for a few more gigabytes of storage before the weekend.
Celera is a bit ahead of that prediction.
When Celera was in the process of selecting the technology to build its global SAN, its primary criteria, in order of importance, were reliability, manageability, scalability, cost and performance.
www.snwonline.com /evaluate/celera_03-10-03.asp?article_id=213   (1242 words)

  
 Celera's About-Face - Forbes.com   (Site not responding. Last check: 2007-09-17)
NEW YORK - Nearly two years after Celera Genomics announced that it had succeeded in its bold sprint to map the human genome, the company is caught in a difficult about-face.
Already, Celera Diagnostics is selling a few tests, and the market for such gene tests is currently at $1 billion and growing 30% per year.
When genomics was still a buzzword, Applied was touted as a sure thing because it sold the machines that are used to sequence genes.
www.forbes.com /technology/ecommerce/2002/04/22/0422celera.html   (902 words)

  
 TIME.com - POY (via CobWeb/3.1 planetlab2.cs.unc.edu)   (Site not responding. Last check: 2007-09-17)
Having the genome in hand will almost certainly be seen as one of the crowning achievements of the new century, no matter what else happens in the next 100 years.
Comparing the human genome with those of other organisms, from bacteria to insects to mammals, will help biologists understand how more complex species evolved from simpler ones¬čand even pinpoint the precise bits of genetic information that are uniquely human.
Some of the discoveries that will flow from the genome sequence (and from the necessary next steps of identifying its genes and specifying their functions) are more or less predictable.
www.time.com.cob-web.org:8888 /time/poy2000/mag/venter.html   (1865 words)

  
 Human Genome News Vol 9(3): July 1998
The Venter-PE plan is to use whole-genome shotgun sequencing, a technique developed by TIGR to sequence much smaller and less complex bacterial genomes that typically have not presented the difficulties already encountered in some regions of human DNA.
However, genome maps at the highest level of resolution --those promised by the genome project--still will be needed as the ultimate tools for scientists to embark on a thorough investigation into human biological function in all its complexity.
When members of the DOE and NIH advisory committees and program staff met with researchers in May to review a draft of a new 5-year plan for the U.S. genome project (FY 1999-FY 2003), they reaffirmed their commitment to delivering a full and highly accurate sequence of the human genome (see New 5-Year Plan).
www.ornl.gov /sci/techresources/Human_Genome/publicat/hgn/v9n3/01venter.shtml   (622 words)

  
 Applera Corporation - Welcome to Applera Corporation (via CobWeb/3.1 planetlab2.cs.unc.edu)   (Site not responding. Last check: 2007-09-17)
The Celera Group (NYSE: CRA) is primarily a molecular diagnostics business that is using proprietary genomics and proteomics discovery platforms to identify and validate novel diagnostic markers, and is developing diagnostic products based on these markers as well as other known markers.
Celera maintains a strategic alliance with Abbott Laboratories for the development and commercialization of molecular, or nucleic acid-based, diagnostic products, and it is also developing new diagnostic products outside of this alliance.
Through its genomics and proteomics research efforts, Celera is also discovering and validating therapeutic targets, and it is seeking strategic partnerships to develop therapeutic products based on these discovered targets.
www.applera.com.cob-web.org:8888   (214 words)

Try your search on: Qwika (all wikis)

Factbites
  About us   |   Why use us?   |   Reviews   |   Press   |   Contact us  
Copyright © 2005-2007 www.factbites.com Usage implies agreement with terms.